Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Lymphocytic Leukemia
Interventions
RP-3500, Olaparib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Terminated Phase 1 Interventional Results available

Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

NCT05147350
Conditions
Advanced Solid Tumor
Interventions
RP-6306 (oral PKMYT1 inhibitor)
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • New York, New York + 2 more
Conditions
Advanced Solid Tumor
Interventions
RP-3467 at assigned dose and schedule, Olaparib 200-300 mg BID, daily
Drug
Lead sponsor
Repare Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
San Francisco, California • St Louis, Missouri • New York, New York + 1 more
Conditions
Solid Tumor, Metastatic Cancer
Interventions
RP-3500, External Beam Radiotherapy (EBRT)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Terminated Phase 1 Interventional Results available

LIONS (PLK4 Inhibitor in Advanced Solid Tumors)

NCT06232408
Conditions
Advanced Solid Tumor
Interventions
RP-1664
Drug
Lead sponsor
Repare Therapeutics
Industry
Eligibility
12 Years to 100 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
San Francisco, California • New Haven, Connecticut • New York, New York
Conditions
Adult Solid Tumor
Interventions
RP-6306 (oral PKMYT1 inhibitor)
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 5 more
Conditions
Advanced Solid Tumor, Adult
Interventions
RP-3500 (camonsertib)
Drug
Lead sponsor
Repare Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 9 more
Completed Phase 1Phase 2 Interventional Results available

Study of RP-3500, Camonsertib, in Advanced Solid Tumors

NCT04497116
Conditions
Advanced Solid Tumor
Interventions
RP-3500 (camonsertib), Talazoparib, Gemcitabine Injection
Drug
Lead sponsor
Repare Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
8
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 4 more